Prometheus Biosciences (RXDX) Stock Price, News & Analysis

Company Overview

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

Key Stats

• Today's Range: $199.92 to $199.92
• 50-Day Range: $192.50 to $199.92
• 52-Week Range: $23.27 to $199.98
• Volume: N/A
• Average Volume: 913,102 shs
• Market Capitalization: $9.56 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RXDX Stock Analysis - Frequently Asked Questions

How were Prometheus Biosciences' earnings last quarter?

Prometheus Biosciences, Inc. (NASDAQ:RXDX) released its quarterly earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.06. The firm's revenue for the quarter was down 71.8% compared to the same quarter last year.

Does Prometheus Biosciences have any subsidiaries?

Prometheus Biosciences subsidiaries include these companies: Prometheus Laboratories Inc..

When did Prometheus Biosciences IPO?

Prometheus Biosciences (RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What other stocks do shareholders of Prometheus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prometheus Biosciences investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Moderna (MRNA).

Company Calendar

• Last Earnings: 5/09/2023
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RXDX
• CUSIP: N/A
• CIK: 1557421
• Web: ignyta.com
• Phone: 858-422-4300
• Fax: N/A
• Employees: 97
• Year Founded: 1995

Profitability

• EPS (Most Recent Fiscal Year): ($3.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-141,750,000.00
• Net Margins: -3,768.76%
• Pretax Margin: -3,768.76%
• Return on Equity: -33.50%
• Return on Assets: -29.59%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 37.56
• Quick Ratio: 37.56

Sales & Book Value

• Annual Sales: $6.81 million
• Price / Sales: 1,403.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.12 per share
• Price / Book: 12.40

Miscellaneous

• Outstanding Shares: 47,810,000
• Free Float: 46,187,000
• Market Cap: $9.56 billion
• Optionable: Not Optionable
• Beta: -0.49